Tekmira Pharmaceuticals Corporation's head office in Burnaby, British Columbia, on Tuesday.
Shares of Tekmira Pharmaceuticals closed at $20.70 on Friday, surging 45% in one day of trading.
On Thursday afternoon, management announced that the FDA loosened a hold on the Ebola treatment in the company's development pipeline.
"[T]he U.S. Food & Drug Administration (FDA) has verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola Investigational New Drug Application (IND) to a partial clinical hold," they said. "This action enables the potential use of TKM-Ebola in individuals infected with Ebola virus."